Spectrophotometric methods for simultaneous estimation of rabeprazole sodium and aceclofenac from the combined capsule dosage form
Introduction: The present work aimed to develop and validate spectrophotometric methods for simultaneous estimation of rabeprazole sodium and aceclofenac in a pure and capsule dosage form. Materials and Methods: Method 1 is based on solving a simultaneous equation. Absorbances of rabeprazole sodium...
Gespeichert in:
Veröffentlicht in: | Pharmaceutical Methods 2011-07, Vol.2 (3), p.193-197 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Introduction: The present work aimed to develop and validate spectrophotometric methods for simultaneous estimation of rabeprazole sodium and aceclofenac in a pure and capsule dosage form. Materials and Methods: Method 1 is based on solving a simultaneous equation. Absorbances of rabeprazole sodium and aceclofenac were measured at their respective absorbance maximas (λmax ) of 283 and 276nm. Method 2 is the Q-analysis or absorption ratio method. Absorbances were measured at 256nm (isosbestic point) and 276nm (λmax of aceclofenac). Methods are validated according to ICH guidelines. Results: A linearity range for rabeprazole sodium and aceclofenac is 10–60μg/ml at respective selected wavelengths. The coefficient of correlation for rabeprazole at 283nm and for aceclofenac at 276nm is 0.9981 and 0.9997, respectively. A percentage estimation of rabeprazole sodium and aceclofenac from the capsule dosage form by method 1 is 100.22 and 99.96 and by method 2 is 99.99 and 100.05, respectively, with a standard deviation less than 2. Conclusion: The proposed methods are simple, rapid, and validated and can be used successfully for routine simultaneous estimation of rabeprazole sodium and aceclofenac in a pure and capsule dosage form. |
---|---|
ISSN: | 2229-4708 2229-4716 |
DOI: | 10.4103/2229-4708.90362 |